Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Race Oncology Ltd. (AU:RAC)
ASX:RAC
RESEARCH TOOLSreports
Holding AU:RAC?
Track your performance easily
RAC Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.64 - AU$2.09
Previous CloseAU$1.7
Volume5.52K
Average Volume (3M)143.97K
Market Cap
AU$287.98M
Enterprise ValueAU$256.18M
Total Cash (Recent Filing)AU$33.54M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding169,376,965
10 Day Avg. Volume75,598
30 Day Avg. Volume143,974
Standard Deviation0.29
R-Squared0.08
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Race Oncology Ltd. News
PremiumCompany Announcements
Race Oncology Expands Shares on ASX
PremiumCompany Announcements
Race Oncology Ltd Expands Market Presence
PremiumCompany Announcements
Race Oncology Options Cease as Conditions UnmetPremiumCompany Announcements
Race Oncology Welcomes New DirectorPremiumCompany Announcements
Race Oncology Welcomes New Director and Shareholder
PremiumCompany Announcements
Race Oncology Announces Director’s Departure and Interests
PremiumCompany Announcements
Race Oncology Announces Director’s Final Notice
PremiumCompany Announcements
Race Oncology Embraces Corporate Governance StandardsOptions Prices
Currently, No data available
---
Ownership Overview
26.34% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
73.66% Public Companies and
Individual Investors
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$0.64 and its highest was AU$2.09 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Currently, no data Available
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Feb 26, 2025 which is in 160 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Aug 27, 2024. The company reported -AU$0.049 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.049.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 170,423,600 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.514%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
---
Race Oncology Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 97%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.85%
12-Months-Change
Fundamentals
Return on Equity
-63.10%
Trailing 12-Months
Asset Growth
-24.06%
Trailing 12-Months
Company Description
Race Oncology Ltd.
Race Oncology Ltd is a specialty pharmaceutical company. It is engaged in the development and marketing of pharmaceutical drugs for the treatment of Cancer. Its product includes Bisantrene, a cancer chemotherapy drug. Its operating segments include research into oncology drugs, Zantrene and the manufacturing and distribution of the drug for clinical trials.
---
Technical Analysis
PYC Therapeutics Limited
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
---